WMT made an splashy entry into the PBM market with new clinics about 6 years ago when it started offering generic perscriptions for $4.00.
So everybody thought that Walmart could use it’s business model and scale up with clinics to be a player in the PBM marketplace.
Walmart also moved into EHC (Electronic Health Record) and in-store clinics with very limited success.
Companies such as WMT and other companies are in a race to build more clinics before 2014 when President Obama’s health care overall will take affect and millions of americans will gain health-insurance coverage.
Right now Walmart lags the industry in the # of clinics
CVS – Caremark has 645 clinics
Walgreens has 347 clinics
Walmart has 141 clinics
So what does this mean for Walmarts bottom line? Today WMT announced that it’s revenue exceeded Wall Street expectations however
it’s gross margin and profit number missed. This is not concerning short term as Walmart attempts to gain back market share that it lost in the last 3 years. The only way to do this is to keep prices low and sacrifice margin.
The primary health care services strategy would act as a “traffic driver” for WMT and that would eventually drive bottom line when prices are increased.
Here’s why WALMART WILL NOT BE A PLAYER IN THE PRIMARY HEALTH CARE SERVICE MARKET
Respondent is responsible for managing the Midwest region for large Biotech firm. He previously worked at Pfizer for 13 years where he launched Viagra, Ziphromax and other $B drugs. He worked as a Region Manager managing hospitals , PBM relationships and over 200 sales representatives responsible for a million dollar book of business.
Participant – 21 years in Pharma and Biotech marketplace. Currently working at Sepracor and previously worked in sales management at Pfizer.
The respondent asked that he not be identified, and that his company not be identified.
What impact could Wal-mart potential entry as a PBM (Pharmacy Benefits manager) would have on the industry, especially the sale of
Pharmaceuticals, and competitive impact/reaction for Target and Walgreen’s and other drugstore retailers. (Impact on traffic, sales,
pricing, etc. for Wal-mart, vs. other drugstore retailers?)
Answer: Mark said “ What a provocative question regarding Wal-Mart entering the PBM arena.
The answer to that is a resounding NO.
Though the PBM business model is run much like the Wal-Mart business model, i.e. brand secondary, cheaper generic (knock
off) alternatives primary, there are several issues which exist that would inhibit Wal-Mart’s ability to be successful in
this area:
1. Other than Wal-Mart employees, most of who are underinsured already, I can’t think of another employer group
eager to be represented by Wal-Mart as their PBM. The brand of Wal-Mart, and their reputation of how their employees are
treated, would not be a good “PR” fit with most employer groups and I would think they’d be a bit hesitant in
diluting their brand with that association.
2. Secondly, PBMs are extremely expensive to run and I can’t think of any competitive advantage they offer against more
veteran PBMs such as Medco and Caremark. For example, the cost eventually the customer sees in the tiered
copay system is absorbed in the current system by the employer, wholesaler and MCO (United, BCBS, ect).
The advantages these firms have are longstanding relationships with major employer groups that will be hard to
supplant. Wal-Mart won’t be able to offer anything different what current PBMs offer, lesser priced drugs (generics) as the
preferred agent with step edits in place to ensure that branded agents are tried only after generics fail.
Most Tier 1 drugs already have a copay that is nominal ($2-$5) Wal-Mart will be unable to offer anything over what that current
PBMs offer other than some sort of point of service discount since they run their own pharmacies. The problem with that
is Caremark and Medco already have lucrative deals in place with Walgreen’s, CVS and Target so I don’t see the business
opportunity for them, especially considering what their margin expectations will be from running the business.
Overall my guess is that, from a distance it appears to be potentially a good opportunity; however when they look at
operation cost and other variables, this will…nowhere. Merck Pharma found this out sometime ago, when it purchased
Medco for 7.2 billion, lost a ton of cash, then divested itself from it. The reasons were not entirely the same; however the
cost was the major issue there as well.
For more in depth analysis and reports contact us at www.57thstventures.com